[1]
|
Wang, C., Horby, P.W., Hayden, F.G., et al. (2020) A Novel Coronavirus Outbreak of Global Health Concern. The Lancet, 395, 470-473. https://doi.org/10.1016/S0140-6736(20)30185-9
|
[2]
|
Kim, D., Lee, J.Y., Yang, J.S., et al. (2020) The Architecture of SARS-CoV-2 Transcriptome. Cell, 181, 914-921.e10.
https://doi.org/10.1016/j.cell.2020.04.011
|
[3]
|
Lv, Z., Deng, Y.Q., Ye, Q., et al. (2020) Structural Basis for Neutralization of SARS-CoV-2 and SARS-CoV by a Potent Therapeutic Antibody. Science, 369, 1505-1509. https://doi.org/10.1126/science.abc5881
|
[4]
|
Wang, X., Cao, R., Zhang, H., et al. (2020) The Anti-Influenza Virus Drug, Arbidol Is an Efficient Inhibitor of SARS-CoV-2 in Vitro. Cell Discovery, 6, 28. https://doi.org/10.1038/s41421-020-0169-8
|
[5]
|
De Vries, R.D., Schmitz, K.S., Bovier, F.T., et al. (2021) Intranasal Fusion Inhibitory Lipopeptide Prevents Direct-Contact SARS-CoV-2 Transmission in Ferrets. Science, 371, 1379-1382. https://doi.org/10.1126/science.abf4896
|
[6]
|
Xia, S., Liu, M., Wang, C., et al. (2020) Inhibition of SARS-CoV-2 (Previously 2019-nCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion. Cell Research, 30, 343-355. https://doi.org/10.1038/s41422-020-0305-x
|
[7]
|
Ling, R., Dai, Y., Huang, B., et al. (2020) In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS- CoV-2. Peptides, 130, Article ID: 170328. https://doi.org/10.1016/j.peptides.2020.170328
|
[8]
|
Hoffmann, M., Schroeder, S., Kleine-Weber, H., et al. (2020) Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrobial Agents and Chemotherapy, 64, e00754-20.
https://doi.org/10.1128/AAC.00754-20
|
[9]
|
Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271-280.e8.
https://doi.org/10.1016/j.cell.2020.02.052
|
[10]
|
Cheng, Y.W., Chao, T.L., Li, C.L., et al. (2020) Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. Cell Reports, 33, Article ID: 108254.
https://doi.org/10.1016/j.celrep.2020.108254
|
[11]
|
Benton, D.J., Wrobel, A.G., Xu, P., et al. (2020) Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion. Nature, 588, 327-330. https://doi.org/10.1038/s41586-020-2772-0
|
[12]
|
Walls, A.C., Park, Y.J., Tortorici, M.A., et al. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181, 281-292 e6. https://doi.org/10.1016/j.cell.2020.02.058
|
[13]
|
Xu, X., Li, G., Sun, B., et al. (2022) S2 Subunit of SARS-CoV-2 Spike Protein Induces Domain Fusion in Natural Pulmonary Surfactant Monolayers. The Journal of Physical Chemistry Letters, 13, 8359-8364.
https://doi.org/10.1021/acs.jpclett.2c01998
|
[14]
|
Chambers, P., Pringle, C.R. and Easton, A.J. (1990) Heptad Repeat Sequences Are Located Adjacent to Hydrophobic Regions in Several Types of Virus Fusion Glycoproteins. Journal of General Virology, 71, 3075-3080.
https://doi.org/10.1099/0022-1317-71-12-3075
|
[15]
|
Kumar, S., Maurya, V.K., Prasad, A.K., et al. (2020) Structural, Glycosylation and Antigenic Variation between 2019 Novel Coronavirus (2019-nCoV) and SARS Coronavirus (SARS-CoV). VirusDisease, 31, 13-21.
https://doi.org/10.1007/s13337-020-00571-5
|
[16]
|
Tang, T., Bidon, M., Jaimes, J.A., et al. (2020) Coronavirus Membrane Fusion Mechanism Offers a Potential Target for Antiviral Development. Antiviral Research, 178, Article ID: 104792.
https://doi.org/10.1016/j.antiviral.2020.104792
|
[17]
|
Xia, X. (2021) Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Viruses, 13, 109. https://doi.org/10.3390/v13010109
|
[18]
|
Coutard, B., Valle, C., De Lamballerie, X., et al. (2020) The Spike Glycoprotein of the New Coronavirus 2019-nCoV Contains a Furin-Like Cleavage Site Absent in CoV of the Same Clade. Antiviral Research, 176, Article ID: 104742.
https://doi.org/10.1016/j.antiviral.2020.104742
|
[19]
|
Yan, R., Zhang, Y., Li, Y., et al. (2020) Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2. Science, 367, 1444-1448. https://doi.org/10.1126/science.abb2762
|
[20]
|
Wu, L., Chen, Q., Liu, K., et al. (2020) Broad Host Range of SARS-CoV-2 and the Molecular Basis for SARS-CoV-2 Binding to Cat ACE2. Cell Discovery, 6, 68. https://doi.org/10.1038/s41421-020-00210-9
|
[21]
|
Liu, K., Tan, S., Niu, S., et al. (2021) Cross-Species Recognition of SARS-CoV-2 to Bat ACE2. Proceedings of the National Academy of Sciences of the United States of America, 118, e2020216118.
https://doi.org/10.1073/pnas.2020216118
|
[22]
|
Peng, R., Wu, L.A., Wang, Q., et al. (2021) Cell Entry by SARS-CoV-2. Trends in Biochemical Sciences, 46, 848-860.
https://doi.org/10.1016/j.tibs.2021.06.001
|
[23]
|
Jackson, C.B., Farzan, M., Chen, B., et al. (2022) Mechanisms of SARS-CoV-2 Entry into Cells. Nature Reviews Molecular Cell Biology, 23, 3-20. https://doi.org/10.1038/s41580-021-00418-x
|
[24]
|
Daly, J.L., Simonetti, B., Klein, K., et al. (2020) Neuropilin-1 Is a Host Factor for SARS-CoV-2 Infection. Science, 370, 861-865. https://doi.org/10.1126/science.abd3072
|
[25]
|
Cantuti-Castelvetri, L., Ojha, R., Pedro, L.D., et al. (2020) Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity. Science, 370, 856-860. https://doi.org/10.1126/science.abd2985
|
[26]
|
Davanzo, G.G., Codo, A.C., Brunetti, N.S., et al. (2020) SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes.
|
[27]
|
Wang, S., Qiu, Z., Hou, Y., et al. (2021) AXL Is a Candidate Receptor for SARS-CoV-2 That Promotes Infection of Pulmonary and Bronchial Epithelial Cells. Cell Research, 31, 126-140. https://doi.org/10.1038/s41422-020-00460-y
|
[28]
|
Wang, K., Chen, W., Zhang, Z., et al. (2020) CD147-Spike Protein Is a Novel Route for SARS-CoV-2 Infection to Host Cells. Signal Transduction and Targeted Therapy, 5, 283. https://doi.org/10.1038/s41392-020-00426-x
|
[29]
|
Gu, Y., Cao, J., Zhang, X., et al. (2022) Receptome Profiling Identifies KREMEN1 and ASGR1 as Alternative Functional Receptors of SARS-CoV-2. Cell Research, 32, 24-37. https://doi.org/10.1038/s41422-021-00595-6
|
[30]
|
Hänel, K. and Willbold, D. (2007) SARS-CoV Accessory Protein 7a Directly Interacts with Human LFA-1. Biological Chemistry, 388, 1325-1332. https://doi.org/10.1515/BC.2007.157
|
[31]
|
Shen, X.R., Geng, R., Li, Q., et al. (2022) ACE2-Independent Infection of T Lymphocytes by SARS-CoV-2. Signal Transduction and Targeted Therapy, 7, 83. https://doi.org/10.1038/s41392-022-00919-x
|
[32]
|
Matsuyama, S. and Taguchi, F. (2009) Two-Step Conformational Changes in a Coronavirus Envelope Glycoprotein Mediated by Receptor Binding and Proteolysis. Journal of Virology, 83, 11133-11141.
https://doi.org/10.1128/JVI.00959-09
|
[33]
|
Kim, Y., Jang, G., Lee, D., et al. (2022) Trypsin Enhances SARS-CoV-2 Infection by Facilitating Viral Entry. Archives of Virology, 167, 441-458. https://doi.org/10.1007/s00705-021-05343-0
|
[34]
|
Ji, H.L., Zhao, R., Matalon, S., et al. (2020) Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiological Reviews, 100, 1065-1075. https://doi.org/10.1152/physrev.00013.2020
|
[35]
|
Cohen, F.S. and Melikyan, G.B. (2004) The Energetics of Membrane Fusion from Binding, through Hemifusion, Pore Formation, and Pore Enlargement. The Journal of Membrane Biology, 199, 1-14.
https://doi.org/10.1007/s00232-004-0669-8
|
[36]
|
Zhang, J., Cai, Y., Xiao, T., et al. (2021) Structural Impact on SARS-CoV-2 Spike Protein by D614G Substitution. Science, 372, 525-530. https://doi.org/10.1126/science.abf2303
|
[37]
|
Bestle, D., Heindl, M.R., Limburg, H., et al. (2020) TMPRSS2 and Furin Are both Essential for Proteolytic Activation of SARS-CoV-2 in Human Airway Cells. Life Science Alliance, 3, e202000786.
https://doi.org/10.1101/2020.04.15.042085
|
[38]
|
Koch, J., Uckeley, Z.M., Doldan, P., et al. (2021) TMPRSS2 Expression Dictates the Entry Route Used by SARS- CoV-2 to Infect Host Cells. The EMBO Journal, 40, e107821. https://doi.org/10.15252/embj.2021107821
|
[39]
|
Wang, P., Lau, S.Y., Deng, S., et al. (2021) Characterization of an Attenuated SARS-CoV-2 Variant with a Deletion at the S1/S2 Junction of the Spike Protein. Nature Communications, 12, 2790.
https://doi.org/10.1038/s41467-021-23166-0
|
[40]
|
Johnson, B.A., Xie, X., Bailey, A.L., et al. (2021) Loss of Furin Cleavage Site Attenuates SARS-CoV-2 Pathogenesis. Nature, 591, 293-299. https://doi.org/10.1038/s41586-021-03237-4
|
[41]
|
Sasaki, M., Toba, S., Itakura, Y., et al. (2021) SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. mBio, 12, e0141521. https://doi.org/10.1128/mBio.01415-21
|
[42]
|
Peacock, T.P., Goldhill, D.H., Zhou, J., et al. (2021) The Furin Cleavage Site in the SARS-CoV-2 Spike Protein Is Required for Transmission in Ferrets. Nature Microbiology, 6, 899-909. https://doi.org/10.1038/s41564-021-00908-w
|
[43]
|
Sasaki, M., Uemura, K., Sato, A., et al. (2021) SARS-CoV-2 Variants with Mutations at the S1/S2 Cleavage Site Are Generated in Vitro during Propagation in TMPRSS2-Deficient Cells. PLOS Pathogens, 17, e1009233.
https://doi.org/10.1371/journal.ppat.1009233
|
[44]
|
Liu, T., Luo, S., Libby, P., et al. (2020) Cathepsin L-Selective Inhibitors: A Potentially Promising Treatment for COVID-19 Patients. Pharmacology & Therapeutics, 213, Article ID: 107587.
https://doi.org/10.1016/j.pharmthera.2020.107587
|